MARKET

PLRX

PLRX

Pliant Therapeutics, Inc.
NASDAQ
1.400
-0.071
-4.80%
Opening 11:46 05/13 EDT
OPEN
1.490
PREV CLOSE
1.470
HIGH
1.490
LOW
1.330
VOLUME
650.52K
TURNOVER
--
52 WEEK HIGH
16.52
52 WEEK LOW
1.100
MARKET CAP
85.91M
P/E (TTM)
-0.3876
1D
5D
1M
3M
1Y
5Y
1D
Cautious Hold Rating on Pliant Therapeutics Amid Clinical and Financial Uncertainties
TipRanks · 1d ago
Cautious Hold Rating for Pliant Therapeutics Amidst Strategic Restructuring and Drug Development Uncertainties
TipRanks · 1d ago
Weekly Report: what happened at PLRX last week (0505-0509)?
Weekly Report · 1d ago
Piper Sandler Keeps Their Buy Rating on Pliant Therapeutics (PLRX)
TipRanks · 4d ago
Oppenheimer Sticks to Its Hold Rating for Pliant Therapeutics (PLRX)
TipRanks · 4d ago
Analysts Have Conflicting Sentiments on These Healthcare Companies: Knight Therapeutics (OtherKHTRF), Pliant Therapeutics (PLRX) and Pacira Pharmaceuticals (PCRX)
TipRanks · 4d ago
Analysts Offer Insights on Healthcare Companies: Trevi Therapeutics (TRVI), Pliant Therapeutics (PLRX) and Qiagen (QGEN)
TipRanks · 4d ago
Pliant Therapeutics GAAP EPS of -$0.92 misses by $0.18
Seeking Alpha · 4d ago
More
About PLRX
More
Pliant Therapeutics, Inc. is a late-stage biotechnology company, which is focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. The Company’s lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of avb6 and avb1 integrins that is in development in the lead indication for the treatment of idiopathic pulmonary fibrosis, or idiopathic pulmonary fibrosis (IPF). The Company’s second clinical program, PLN-101095, is a small molecule, dual selective inhibitor of integrins avb8 and avb1 for the treatment of solid tumors that are resistant to immune checkpoint inhibitors. Its Phase 1-ready program PLN-101325, is in development for treatment of muscular dystrophies, including Duchenne muscular dystrophy. PLN-101325 is a monoclonal antibody designed to act as an allosteric agonist of integrin a7b1.
Recently
Symbol
Price
%Change

Webull offers Pliant Therapeutics Inc stock information, including NASDAQ: PLRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PLRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PLRX stock methods without spending real money on the virtual paper trading platform.